Inhibikase Therapeutics (IKT) Earnings Date & Reports

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

IKT is expected to report earnings to -10 cents per share on November 16

Inhibikase Therapeutics IKT Stock Earnings Reports

Q3'26

Est.

$-0.11

Q2'26

Est.

$-0.11

Q1'26

Beat

by $0.07

Q4'25

Beat

by $0.08

Q3'25

Beat

by $0.01

The last earnings report on August 11 showed earnings per share of -10 cents, meeting the estimate of -10 cents. With 203.18K shares outstanding, the current market capitalization sits at 300.00M.

View a ticker or compare two or three

IKT

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for IKT